Share

September 23, 2014; 83 (13) Article

Central poststroke pain in young ischemic stroke survivors in the Helsinki Young Stroke Registry

Hanna Harno, Elena Haapaniemi, Jukka Putaala, Maija Haanpää, Jyrki P. Mäkelä, Eija Kalso, Turgut Tatlisumak
First published August 15, 2014, DOI: https://doi.org/10.1212/WNL.0000000000000818
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
239

Share

Article Information

vol. 83 no. 13 1147-1154
DOI: 
https://doi.org/10.1212/WNL.0000000000000818
PubMed: 
25128182
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 20, 2014
  • Accepted in final form June 27, 2014
  • First Published August 15, 2014.

Article Versions

Copyright & Usage: 
© 2014 American Academy of Neurology

Author Disclosures

    1. Hanna Harno, MD, PhD,
    2. Elena Haapaniemi, MD, PhD,
    3. Jukka Putaala, MD, PhD,
    4. Maija Haanpää, MD, PhD,
    5. Jyrki P. Mäkelä, MD, PhD,
    6. Eija Kalso, MD, PhD and
    7. Turgut Tatlisumak, MD, PhD
  1. Hanna Harno, MD, PhD,
    2. Scientific Advisory Boards:

    1. (1) Served on a scientific advisory board for Allergan.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Funding for travel to a conference by Novartis.(2) Speaker honoraria by Pfizer.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Elena Haapaniemi, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jukka Putaala, MD, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Congress travel grants: Boehringer-Ingelheim, Genzyme Speaker honoraria: Orion Pharma, Boehringer-Ingelheim, Genzyme

    Editorial Boards:

    1. Editorial review borad: Frontiers in Stroke (2010-), no compensation; Finnish Medical Journal (2014-), no compensation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Helsinki and Uusimaa Hospital District research fund, (2) Finnish Medical Foundation, (3) Diabetes Wellness Finland

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Maija Haanpää, MD, PhD,
    5. Scientific Advisory Boards:

    1. Advisory boards of Allergan, Astellas and Pfizer.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Lecture fees from Astellas, Eli Lilly, Janssen-Cilag, MSD, Mundipharma, Orion, Pfizer and Sanofi-Aventis.

    Editorial Boards:

    1. Editorial board member for Pain, European Journal of Pain and Scandinavian Journal of Pain, no monetary compensation received.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Jyrki P. Mäkelä, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Nexstim Inc. Funding for travel Elekta Inc. Funding for travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Finnish Funding Agency for Technology and Innovation/ Strategic Centre for Health and well-being

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Eija Kalso, MD, PhD and
    7. Scientific Advisory Boards:

    1. (1) Commercial entity: Orion Pharma (2) Commercial entity: Pharmaleads (3) Commercial entity: Gruenenthal

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Commercial: Mundipharma

    Editorial Boards:

    1. (1) European Journal of Pain: Associate Editor (>10 years) (2) Scandinavian Journal of Pain: Editorial Board (5 years)

    Patents:

    1. (1) a new alphaa-2-adrenergic agonist (2) oxymorphone for intrathecal administration

    Publishing Royalties:

    1. Duodecim Oy, (The Finnish Medical Society): textbook chapters about pain

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Governmental (Finnish) funding for university level health research: TYH2012212 (2012-2013), TYH2013311 (2013-2015)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Finska L�kares�llskapet (2) P�ivikki and Sakari Sohlberg Foundation (3) Cancer Foundation Finland

    Stock/Stock Options/Board of Directors Compensation:

    1. (1) Commercial entity: Orion Pharma

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Turgut Tatlisumak, MD, PhD
    8. Scientific Advisory Boards:

    1. Boehringer-Ingelheim Mitsubishi Pharma PhotoThera BrainsGate H. Lundbeck A/S Orion Pharma Bayer

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Boehringer Ingelheim (travel expenses to 1 conference) Professio Finland (speaker honoraria) University of Helsinki (speaker honoraria) Finnish Medical Association (speaker honoraria) University of Donau (Austria, speaker honoraria) Genzyme Oy (Finland, speaker honoraria) Finnish Neurological Association (speaker honoraria) Australia-NZ Stroke Association (speaker honoraria) Congress traveling and accommodation costs: European Stroke Conference European Federation of Neurological Societies European Stroke Organisation L�ANTEL telemedicine conference (France) University of Rostock (Germany) University of Bielefeld (Germany) SITS International Boehringer Ingelheim University of Donau (Austria) Catholic University of Leuven (Belgium) Austrian Stroke Society University of Oulu (Finland) Nordic Stroke Conference Australia-NZ Stroke Association Polish Neuroscience Socitey Internal Medicine Socitey of Greece World Stroke Conference Thrombolysis and Thrombectomy in Acute Stroke Treatment Conference

    Editorial Boards:

    1. Stroke, 2000-2006, 2010-Current Vascular Pharmacology, 2002-The Open Pharmacology Journal 2007-2010 Clinics of Turkey 2007-2012 Clinics of Turkey / Neurology 2007-2012 The Open Cardiovascular Medicine Journal 2007 Recent Patents on Biotechnology 2008 Recent Patents on CNS Drug Discovery, 2008-2010 Experimental and Translational Stroke Medicine, 2008-2009 Stroke Research and Treatment, 2009-BMC Journal of Experimental and Translational Stroke Medicine, 2009-Frontiers in Stroke, 2010-Case Reports in Neurology (founding editor-in-chief)2009-2012 Cerebrovascular Diseases, 2011-No compensation was received for any of the above editorial duties

    Patents:

    1. 1.Stanniocalcin proteins and nucleic acids and methods based thereon. Application No/ Patent No: WO0130969, Publication date: 2001-05-03, requested patent: EP1233778, Inventors: Olsen HS, Zhang K, Lindsberg P, Tatlisumak T, Kaste M, Andersson LC. Human Genome Sciences Inc (US), Application number: WO2000US29432 2000010262.New Therapeutic Uses (method to prevent brain edema and reperfusion injury), PCT/FI2004/000070. Inventors: Lindsberg PJ, Karjalainen-Lindsberg M-L, Tatlisumak T, Strbian D. Applicant: Licentia Oy. Application date: February 13, 2003. Publication 7/2003, Application number: 20030224. 3.Thrombolytic compositions (method to prevent postthrombolytic hemorrhage formation), PCT/FI2004/000071. Inventors: Lindsberg PJ, Karjalainen-Lindsberg M-L, Tatlisumak T, Strbian D, Kovanen P. Applicant: Licentia Oy. Application date: February 13, 2003. Publication: 3/2003. Application number: 20030225.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Boehringer Ingelheim, PhotoThera, BrainsGate, H. Lundbeck A/B, Orion, Bayer

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. I was in capacity of receiving for editing 1 book for Cambridge Univ Press (donated to British Red Cross) and being an editor-in-chief for Case Reports in Neurology Journal (donated to Swiss Red Cross).

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Helsinki University Central Hospital Research Funds European Union, EU FP7 202213, 2008-2012, PI Biocentrum Finland, 2010-2012 Biocentrum Helsinki, 2011, 2012, 2013 Finnish Academy of Sciences, 2012-2014 National Institutes of Health

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Sigrid Juselius Foundation, 2010, PI Maire Taponen Foundation, 2012 Sigrid Juselius Foundation, 2014, PI

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Neurology (H.H., E.H., J.P., T.T.), Neurosurgery (M.H.), and Anesthesiology (E.K.), and BioMag Laboratory, HUS Medical Imaging Center (J.P.M.), Helsinki University Central Hospital; and Etera Mutual Pension Insurance Company (M.H.), Helsinki, Finland.
  1. Correspondence to Dr. Harno:hanna.harno{at}hus.fi
View Full Text

Article usage

Article usage: August 2014 to July 2022

AbstractFullPdfSource
Aug 2014728015Highwire
Sep 201411237952Highwire
Oct 20144259723Highwire
Nov 2014117358Highwire
Dec 201492429Highwire
Jan 2015103153Highwire
Feb 201546227Highwire
Mar 201575102Highwire
Apr 20154273Highwire
May 20153396Highwire
Jun 20153453Highwire
Jul 20153785Highwire
Aug 20152583Highwire
Sep 20152352Highwire
Oct 20154081Highwire
Nov 20152895Highwire
Dec 20152052Highwire
Jan 201647113Highwire
Feb 20162456Highwire
Mar 201619104Highwire
Apr 20162131Highwire
May 20161332Highwire
Jun 20161443Highwire
Jul 20161212Highwire
Aug 20162121Highwire
Sep 20161421Highwire
Oct 20163200Highwire
Nov 20161621Highwire
Dec 20161511Highwire
Jan 20173132Highwire
Feb 20172311Highwire
Mar 20172400Highwire
Apr 20172411Highwire
May 20173321Highwire
Jun 20171242Highwire
Jul 20171110Highwire
Aug 20171522Highwire
Sep 2017932Highwire
Oct 2017933Highwire
Nov 2017753Highwire
Dec 20171910Highwire
Jan 20182214Highwire
Feb 20181900Highwire
Mar 20182301Highwire
Apr 20183412Highwire
May 20183100Highwire
Jun 20183301Highwire
Jul 20181110Highwire
Aug 20181610Highwire
Sep 20183031Highwire
Oct 20182411Highwire
Nov 20182900Highwire
Dec 20182811Highwire
Jan 20191811Highwire
Feb 20191100Highwire
Mar 20191300Highwire
Apr 20193311Highwire
May 20191000Highwire
Jun 20191010Highwire
Jul 20192200Highwire
Aug 20192000Highwire
Sep 20191801Highwire
Oct 20192400Highwire
Nov 20193410Highwire
Dec 20192212Highwire
Jan 20202510Highwire
Feb 20202952Highwire
Mar 20203101Highwire
Apr 20202733Highwire
May 20201722Highwire
Jun 2020911Highwire
Jul 20202504Highwire
Aug 20201601Highwire
Sep 20202011Highwire
Oct 20203600Highwire
Nov 20203130Highwire
Dec 20202000Highwire
Jan 20217300Highwire
Feb 20213211Highwire
Mar 20212811Highwire
Apr 20213410Highwire
May 20213221Highwire
Jun 20214311Highwire
Jul 20212022Highwire
Aug 20214310Highwire
Sep 20215453Highwire
Oct 20215301Highwire
Nov 20215890Highwire
Dec 20212010Highwire
Jan 20226700Highwire
Feb 20229113Highwire
Mar 20222801Highwire
Apr 20223011Highwire
May 20223200Highwire
Jun 20223921Highwire
Jul 20221201Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Topics Discussed

Alert Me